Acetaminophen and Social Processes
Last updated on April 2022Recruitment
- Recruitment Status
- Unknown status
Inclusion Criteria
- 18 years or older
- if on psychiatric medication, must be on a stable dose
- able to swallow tablets
- ...
- 18 years or older
- if on psychiatric medication, must be on a stable dose
- able to swallow tablets
- clinical diagnosis of borderline personality disorder
Exclusion Criteria
- Conditions that can affect immune system functioning.
- pregnancy
- current, primary substance abuse, particularly alcoholism
- ...
- Conditions that can affect immune system functioning.
- pregnancy
- current, primary substance abuse, particularly alcoholism
- current eating disorder
- history or current psychotic disorder
- suicidal ideation or behavior requiring imminent inpatient treatment
- Impaired liver function (> 1.25x the upper limit of the reference range)
- Participants whose medication has not been stable for more than 4 weeks
Summary
- Conditions
- Borderline Personality Disorder
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
Participation Requirements
- Age
- Between 18 years and 50 years
- Gender
- Only females
Inclusion Criteria
- 18 years or older
- if on psychiatric medication, must be on a stable dose
- able to swallow tablets
- ...
- 18 years or older
- if on psychiatric medication, must be on a stable dose
- able to swallow tablets
- clinical diagnosis of borderline personality disorder
Exclusion Criteria
- Conditions that can affect immune system functioning.
- pregnancy
- current, primary substance abuse, particularly alcoholism
- ...
- Conditions that can affect immune system functioning.
- pregnancy
- current, primary substance abuse, particularly alcoholism
- current eating disorder
- history or current psychotic disorder
- suicidal ideation or behavior requiring imminent inpatient treatment
- Impaired liver function (> 1.25x the upper limit of the reference range)
- Participants whose medication has not been stable for more than 4 weeks
Tracking Information
- NCT #
- NCT02108990
- Collaborators
- National Center for Advancing Translational Science (NCATS)
- Investigators
- Principal Investigator: Baldwin M Way, Ph.D. Ohio State University Principal Investigator: Jennifer S. Cheavens, Ph.D. Ohio State University
- Baldwin M Way, Ph.D. Ohio State University Principal Investigator: Jennifer S. Cheavens, Ph.D. Ohio State University
Get Well Soon